Skip to Content

UK Edition. Click here for US version.

MONTELUKAST PAEDIATRIC 5 MG CHEWABLE TABLETS

Active substance(s): MONTELUKAST / MONTELUKAST SODIUM

PDF options:  View Fullscreen   Download PDF

PDF Transcript

1. What Montelukast Paediatric is and what it is used for
Montelukast Paediatric contains the active substance montelukast. Montelukast Paediatric is a leukotriene receptor antagonist that blocks substances called leukotrienes. Leukotrienes cause narrowing and
swelling of airways in the lungs. By blocking leukotrienes, Montelukast Paediatric improves asthma
symptoms and helps control asthma.
Your or your child’s doctor has prescribed Montelukast Paediatric to treat asthma, preventing your or
your child’s asthma symptoms during the day and night.
• Montelukast Paediatric is used for the treatment of patients who are not adequately controlled on
their medication and need additional therapy.
• Montelukast Paediatric may also be used as an alternative treatment to inhaled corticosteroids for
6 to 14 year old patients who have not recently taken oral corticosteroids for their asthma and
have shown that they are unable to use inhaled corticosteroids.
• Montelukast Paediatric also helps prevent the narrowing of airways triggered by exercise.
Your or your child’s doctor will determine how Montelukast Paediatric should be used depending on the
symptoms and severity of your or your child's asthma.
What is asthma?
Asthma is a long-term disease.
Asthma includes:
• Difficulty breathing because of narrowed airways. This narrowing of airways worsens and
improves in response to various conditions.
• Sensitive airways that react to many things, such as cigarette smoke, pollen, cold air, or exercise.
• Swelling (inflammation) in the lining of the airways.
Symptoms of asthma include: Coughing, wheezing, and chest tightness.

2. What you need to know before you or your child takes Montelukast Paediatric
Tell your doctor about any medical problems or allergies you or your child has now or has had.
Do not take Montelukast Paediatric if you or your child
• are/ is allergic (hypersensitive) to montelukast or any of the other ingredients of Montelukast
Paediatric (listed in section 6).
Warnings and precautions
Talk to your or your child’s doctors or pharmacist before you or your child takes Montelukast
Paediatric.
Take special care with Montelukast Paediatric
• If you or your child’s asthma or breathing gets worse, tell your doctor immediately.
• Oral Montelukast Paediatric is not meant to treat acute asthma attacks. If an attack occurs, follow
the instructions your doctor has given you or your child. Always have your inhaled rescue
medicine for asthma attacks with you.
• It is important that you or your child take all asthma medications prescribed by your doctor.

Montelukast Paediatric
5 mg chewable tablets

21049556

3. How to take Montelukast Paediatric
• You or your child should take only one tablet of Montelukast Paediatric once a day as prescribed by your
doctor.
• It should be taken even when you or your child has no symptoms or has an acute asthma attack.
• Always take Montelukast Paediatric exactly as your or your child’s doctor or pharmacist has told you.
Check with your or you child’s doctor or pharmacist if you are not sure.
• To be taken by mouth.
Use in children and adolescents:
For children 6 to 14 years of age:
One Montelukast Paediatric 5 mg chewable tablet daily to be taken in the evening. Montelukast Paediatric 5
mg chewable tablets should not be taken immediately with food; it should be taken at least 1 hour before or 2
hours after food.
If you or your child is taking Montelukast Paediatric, be sure that you or your child does not take any other
medicines that contain the same active ingredient, montelukast.
If you or your child takes more Montelukast Paediatric than you or he/ she should
Contact your or your child’s doctor immediately for advice.
There were no side effects reported in the majority of overdose reports. The most frequently occurring
symptoms reported with overdose in adults and children included abdominal pain, sleepiness, thirst,
headache, vomiting, and hyperactivity.

21049556

What is in this leaflet:
1. What Montelukast Paediatric is and what it is used for
2. What you need to know before you or your child takes Montelukast Paediatric
3. How to take Montelukast Paediatric
4. Possible side effects
5. How to store Montelukast Paediatric
6. Contents of the pack and other information

UK

Montelukast Paediatric
5 mg chewable tablets

Read all of this leaflet carefully before you or your child starts taking this medicine because it
contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, please ask your or your child’s doctor or pharmacist.
• This medicine has been prescribed for you or your child. Do not pass it on to others. It may harm
them, even if their signs of illness are the same as yours or your child’s.
• If you or your child gets any side effects, talk to your or your child’s doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See section 4.

Montelukast Paediatric should not be used instead of other asthma medications your doctor has
prescribed for you or your child.
• If you or child are on anti-asthma medicines, be aware that if you or your child develops a combination
of symptoms such as flu-like illness, pins and needles or numbness of arms or legs, worsening of
pulmonary symptoms, and/or rash, you should consult your or your child’s doctor.
• You or your child should not take acetyl-salicylic acid (aspirin) or anti-inflammatory medicines (also
known as non-steroidal anti-inflammatory drugs or NSAIDs) if they make your or your child’s asthma
worse.
Children
For children 2 to 5 years old, Montelukast Paediatric 4 mg chewable tablets are available.
For children 6 to 14 years old, Montelukast Paediatric 5 mg chewable tablets are available.
Other medicines and Montelukast Paediatric
Some medicines may affect how Montelukast Paediatric works, or Montelukast Paediatric may affect how
other medicines work.
Tell your or your child’s doctor or pharmacist if you or your child is taking or has recently taken any other
medicines, including those obtained without a prescription.
Tell your or your child’s doctor if you or your child is taking the following medicines before starting
Montelukast Paediatric:
• Phenobarbital (used for treatment of epilepsy)
• Phenytoin (used for treatment of epilepsy)
• Rifampicin (used to treat tuberculosis and some other infections)
Montelukast Paediatric with food
Montelukast Paediatric 5 mg chewable tablets should not be taken immediately with food; they should be
taken at least 1 hour before or 2 hours after food.
Pregnancy and breast-feeding
Pregnancy
Women who are pregnant or intend to become pregnant should consult their doctor before taking
Montelukast Paediatric. Your doctor will assess whether you can take Montelukast Paediatric during this
time.
Breast-feeding
It is not known if montelukast appears in breast milk. You should consult your doctor before taking
Montelukast Paediatric if you are breast-feeding or intend to breast-feed.
Driving and using machines
Montelukast Paediatric is not expected to affect your ability to drive a car or operate machinery. However,
individual responses to medication may vary. Certain side effects (such as dizziness and drowsiness) that
have been reported very rarely with Montelukast may affect some patients’ ability to drive or operate
machinery.
Montelukast Paediatric contains aspartame
Montelukast Paediatric chewable tablets contain aspartame, a source of phenylalanine. May be harmful for
people with phenylketonuria.

21049556

Package leaflet: Information for the user
Montelukast Paediatric 5 mg chewable tablets
montelukast

4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
In clinical studies with Montelukast Paediatric 5 mg chewable tablets, the most commonly reported side
effects (occurring in at least 1 of 100 patients and less than 1 of 10 paediatric patients treated) thought to be
related to Montelukast Paediatric were:
• Headache
Additionally, the following side effect was reported in clinical studies with Montelukast 10 mg film-coated
tablets:
• Abdominal pain
These were usually mild and occurred at a greater frequency in patients treated with Montelukast than
placebo (a pill containing no medication).
Additionally, while the medicine has been on the market, the following have been reported:
Very common: may affect more than 1 in 10 people
• upper respiratory infection
Common: may affect up to 1 in 10 people
• diarrhoea, nausea, vomiting
• rash
• fever
Uncommon: may affect up to 1 in 100 people
• allergic reactions including swelling of the face, lips, tongue, and/or throat which may cause difficulty in
breathing or swallowing
• behaviour and mood related changes [dream abnormalities, including nightmares, trouble sleeping, sleep
walking, irritability, feeling anxious, restlessness, agitation including aggressive behaviour or hostility,
depression]
• dizziness, drowsiness, pins and needles/numbness, seizure
• nosebleed
• dry mouth, indigestion
• bruising, itching, hives
• joint or muscle pain, muscle cramps
• tiredness, feeling unwell, swelling
Rare: may affect up to 1 in 1,000 people
• increased bleeding tendency
• tremor
• disturbance in attention
• memory impairment
• Serious allergic reaction which causes swelling of the face or throat
• palpitations
Very rare: may affect up to 1 in 10,000 people
• behaviour and mood related changes [hallucinations, disorientation, suicidal thoughts and actions]
• hepatitis (inflammation of the liver)
• tender red lumps under the skin most commonly on your shins (erythema nodosum), severe skin reaction
(erythema multiforme) that may occur without warning
• Coughing, wheezing, shortness of breath and a high temperature, which are symptoms of inflammation of
the lungs associated with an increase in white blood cells (pulmonary eosinophilia)
In asthmatic patients treated with montelukast, very rare cases of a combination of symptoms such as flu-like
illness, pins and needles or numbness of arms and legs, worsening of pulmonary symptoms and/or rash
(Churg-Strauss syndrome) have been reported. You must tell your doctor right away if you get one or more
of these symptoms.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety
of this medicine.

5. How to store Montelukast Paediatric
• Keep this medicine out of the sight and reach of children.
• Do not use this medicine after the expiry date which is stated on the label/ carton/ blister. The expiry date
refers to the last day of that month.
• Store in the original package in order to protect from light and moisture.
• Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information
What Montelukast Paediatric contains
• The active substance is montelukast. Each tablet contains montelukast sodium which corresponds to 5
milligram of montelukast.
• The other ingredients are:
Mannitol, microcrystalline cellulose, hydroxypropyl cellulose (E 463), red iron oxide (E 172), croscarmellose sodium, cherry flavour (contains maltodextrin (Maize), nature identical flavouring substance, acacia
gum (E 414), propylene glycol, flavouring preparation and natural flavouring substance), aspartame
(E951), and magnesium stearate.
What Montelukast Paediatric looks like and contents of the pack
Montelukast Paediatric 5 mg chewable tablets are pink-coloured, circular, biconvex, uncoated chewable
tablets debossed with '5' on one side and plain on other side.
Blisters in packages of: 10, 14, 28, 56 and 100 tablets.
Not all pack sizes may be marketed
Marketing Authorisation Holder and Manufacturer
The Marketing Authorisation Holder is Relonchem Limited, Cheshire House, Gorsey Lane, Widnes, Cheshire,
WA8 0RP, United Kingdom
Manufacturer
Pharmadox Healthcare Ltd., KW20A Kordin Industrial Park, Paola, PLA 3000, Malta
S&D Pharma CZ, spol. s r.o. Theodor 28, 273 08 Pchery (Pharmos a.s. facility), Czech republic
Cipla (EU) Limited, 20 Balderton Street, London, W1K 6TL, United Kingdom
Cipla Europe NV, Uitbreidingstraat 80, 2600 Antwerp, Belgium
This leaflet was last revised in October 2017

21049556

If you forget to take Montelukast Paediatric or give Montelukast Paediatric to your child
Try to take Montelukast Paediatric as prescribed. However, if you or your child misses a dose, just resume
the usual schedule of one tablet once daily.
Do not take a double dose to make up for a forgotten dose.
If you or your child stops taking Montelukast Paediatric
Montelukast Paediatric can treat you or your child’s asthma only if you or your child continues to taking it.
It is important to continue taking Montelukast Paediatric for as long as your doctor prescribes. It will help
control you or your child’s asthma.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

UK

UK

PACKAGING DEVELOPMENT
Product Name : Montelukast Paediatric 5mg

Coordinator : Shweta

Item Code : 21049556
Artist : Atul

Item : PIL
Date : 21-08-15
Software : Illustrator CS5

Font : Times New Roman

Fonts : Convert to curve

Heading : 12pt

Colours :

Pantone Black C

BLUE WOOL TEST VALUE 5-8
(LIGHT FASTENING DATA)

INK: Oil based Ink from DIC OR MICRO
Spectro-Densitometer Delta-E reading
( E) for colour: NOT MORE THAN dE2.5
Supersedes / Reference :
Tuck flap:

Glossmeter reading
(for white surface): NOT LESS THAN 80 %
Screen : # 150

Side / Collar flap overlap:

Unwinding Direction :

Caliper (Thickness) for Board:

Links :
2Dcode : XXXXXXXX

Design : Folded

Material : 42 GSM ITC Paper with perforated printed/ plain tear here tape

Varnish :

Actual Size : 348 x 250mm

Size after Folding : 50 x 40mm

Print repeat length :
Grain Direction : Perpendicular to Crease / Perpendicular to Pasting Flap / Parallel to length
Reference / Instructions / Remark / Braille Text Embossing:
Artwork Print Size:

actual

scaled

Path : mac/Cipla (EU)/Own Launch/21049556 Montelukast Paediatric 5mg Tablets (Safety variation) Cipla (EU)
PIL.ai
Checked by

Artist

Cordinator

Section Head

File Copied by:

file loaded in BCT HO

Pharma Code
2D Code
Barcode Code
Artwork
Spell check

Date:

NOTE TO THE PRINTER :

Return approved artwork alongwith the proof.

The proof must be verified against the approved hardcopy, should be certified and signed by an
authorised QA person. The unsigned proof will not be accepted.

Colour scheme must be as approved by packaging development co-ordinator.

Any deviation must be brought to the notice of packaging development co-ordinator immediately.

For any clarification, please contact packaging development co-ordinator immediately.

Subheading : 10pt
Body text: 9pt

+ Expand Transcript

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide